Bufuralol Hydrochloride: β-Adrenergic Modulation for Cardiovascular Pharmacology Research

Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline, non-selective β-adrenergic receptor antagonist essential in cardiovascular pharmacology research (APExBIO). It demonstrates partial intrinsic sympathomimetic activity, allowing nuanced modulation of β-adrenoceptor signaling (Saito et al., 2025). Bufuralol hydrochloride is benchmarked for its prolonged inhibitory effect on exercise-induced heart rate, comparable to propranolol. Its membrane-stabilizing properties are validated in vitro. The compound is increasingly integrated into advanced pharmacokinetic models, such as human iPSC-derived intestinal organoids, to simulate human-relevant absorption and metabolism (Saito et al., 2025).

Biological Rationale

Bufuralol hydrochloride is a small molecule antagonist targeting β-adrenergic receptors. These receptors mediate cardiovascular, pulmonary, and metabolic responses to catecholamines. In cardiovascular systems, β-adrenoceptors regulate heart rate, contractility, and vascular tone. Non-selective antagonists like bufuralol are essential for dissecting the physiological and pharmacological roles of both β1 and β2 receptor subtypes. Their use enables precise interrogation of sympathetic nervous system modulation in both experimental and translational research (Saito et al., 2025).

Recent advances in human pluripotent stem cell-derived intestinal organoids allow for modeling of oral bioavailability and metabolism of β-blockers. Such models provide improved predictivity compared to traditional Caco-2 cell lines, as they recapitulate CYP3A4 expression and transporter activity found in human enterocytes (Saito et al., 2025).

Mechanism of Action of Bufuralol hydrochloride

Bufuralol hydrochloride acts as a non-selective β-adrenergic receptor antagonist, blocking both β1 and β2 adrenoceptors. This inhibition reduces catecholamine-mediated cardiac stimulation, leading to decreased heart rate and contractility. Bufuralol also displays partial intrinsic sympathomimetic activity (ISA), evidenced by its ability to induce tachycardia in animal models with depleted catecholamine stores (Saito et al., 2025). This feature distinguishes it from pure antagonists and allows fine-tuned modulation of receptor signaling.

In vitro, bufuralol demonstrates membrane-stabilizing effects, which may contribute to its anti-arrhythmic properties. The drug’s partial agonist activity is quantitatively characterized by its impact on cyclic AMP generation and heart rate modulation in isolated tissue experiments. Its molecular formula is C16H23NO2·HCl, with a molecular weight of 297.8 Da. Solubility parameters are: 15 mg/ml in ethanol, 10 mg/ml in DMSO, and 15 mg/ml in dimethyl formamide. Stability is ensured at -20°C, but prompt use of working solutions is recommended (APExBIO).

Evidence & Benchmarks

• Bufuralol hydrochloride exhibits non-selective antagonism of β1 and β2 adrenoceptors, as confirmed by competitive binding assays and functional tissue studies (Saito et al., 2025).
• Partial intrinsic sympathomimetic activity is validated by its tachycardic effect in catecholamine-depleted animal models (Saito et al., 2025).
• Bufuralol hydrochloride’s membrane-stabilizing properties are demonstrated in vitro by reduced excitability of cardiac myocytes at concentrations up to 10 µM (pH 7.4, 37°C) (Saito et al., 2025).
• Exercise-induced heart rate inhibition is prolonged with bufuralol, matching the efficacy of propranolol in double-blind clinical comparisons (Saito et al., 2025).
• Human iPSC-derived intestinal organoids provide a superior model for bufuralol pharmacokinetics, recapitulating CYP3A-mediated metabolism and P-gp efflux, surpassing traditional Caco-2 cells (Saito et al., 2025).

Compared to related articles, this review extends the mechanistic discussion in "Bufuralol Hydrochloride: Expanding Horizons in β-Adrenerg..." by providing updated benchmarks from iPSC-derived organoid models. It also clarifies application boundaries versus "Bufuralol Hydrochloride in Precision β-Adrenergic Modulat..." by specifying solution stability and critical workflow integration steps.

Applications, Limits & Misconceptions

Bufuralol hydrochloride is broadly used in β-adrenergic modulation studies, cardiovascular disease research, and advanced in vitro pharmacokinetic modeling. It enables investigation of beta-adrenoceptor signaling pathways, heart rate regulation, and membrane stabilization effects. The compound is increasingly applied in precision medicine studies using iPSC-derived organoid systems, reflecting human-relevant absorption and metabolism (Saito et al., 2025).

However, bufuralol hydrochloride is not β1-selective and should not be used for studies requiring subtype specificity. Its partial agonist activity can confound interpretation in systems lacking endogenous catecholamines. Long-term solution stability is limited; solutions should be prepared fresh and used promptly. The compound’s applicability in non-mammalian models is unproven.

Common Pitfalls or Misconceptions

• Assuming bufuralol hydrochloride is β1-selective—It is non-selective and blocks both β1 and β2 adrenoceptors.
• Using old or improperly stored solutions—Degradation can reduce efficacy; always prepare fresh solutions and store at -20°C.
• Expecting pure antagonism—Partial intrinsic sympathomimetic activity may yield unexpected agonist-like effects, especially in catecholamine-depleted systems.
• Applying to non-mammalian models—Species differences in β-adrenoceptor structure may invalidate extrapolations.
• Overreliance on Caco-2 cells—For human-relevant metabolism, iPSC-derived intestinal organoids are preferred (Saito et al., 2025).

Workflow Integration & Parameters

Researchers should source bufuralol hydrochloride from reputable suppliers such as APExBIO (SKU C5043) to ensure batch consistency. For in vitro studies, dissolve bufuralol hydrochloride at up to 15 mg/ml in ethanol, 10 mg/ml in DMSO, or 15 mg/ml in dimethyl formamide. Store stock solutions at -20°C; working solutions should be used within 24 hours to maintain activity. For pharmacokinetic modeling, integrate bufuralol with human iPSC-derived intestinal organoids following established protocols (Saito et al., 2025).

In cardiovascular models, use concentrations between 1–10 µM for receptor blockade assays. For membrane stabilization studies, align with published protocols using pH 7.4 buffers at 37°C. Report all quantitative conditions and link to relevant controls. Protocol-driven integration, as detailed in "Bufuralol Hydrochloride: Unlocking Advanced β-Adrenergic ...", enables troubleshooting and reproducibility in next-generation β-adrenergic modulation research.

Conclusion & Outlook

Bufuralol hydrochloride remains a gold standard for non-selective β-adrenergic receptor blockade in cardiovascular pharmacology. Its partial intrinsic sympathomimetic activity and membrane-stabilizing effects provide nuanced tools for dissecting β-adrenoceptor signaling. Integration with human iPSC-derived organoid platforms enhances translational relevance for metabolism and pharmacokinetic studies. Future research will benefit from standardized workflows and cross-platform benchmarking. APExBIO continues to support the research community with high-quality bufuralol hydrochloride for advanced β-adrenergic modulation studies.